RWS of Inetetamab HER2 Positive Advanced Breast Cancer
This non-Interventional study will describe and analyze the clinical use of Inetetamab in clinical practice in the treatment of HER2 positive advanced breast cancer in the real world.
HER2-positive Advanced Breast Cancer
DRUG: Inetetamab
Progression Free Survival(PFS), 12 months|Incidences of adverse events and toxicities, 12 months
This non-Interventional study will describe and analyze the clinical use of Inetetamab in clinical practice in the treatment of HER2 positive advanced breast cancer in the real world.